| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615721 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 27 Pages |
Abstract
Among patients with relapsed CBF-AML, median survival was less than a year and half and the outcome was worse in patients with t (8;21). Despite the relatively better outcomes, dedicated clinical trials are needed to improve the outcome in all patients with relapsed CBF-AML.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Maliha Khan, Jorge Cortes, Wei Qiao, Mohanad A. Alzubaidi, Sherry A. Pierce, Farhad Ravandi, Hagop M. Kantarjian, Gautam Borthakur,